NCT06014944

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody

A Single-arm, Single-center, Prospective Clinical Study of Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody for Neoadjuvant Therapy of PMMR/MSS Type Middle and Low Locally Advanced Rectal Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Changhai Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The investigators conduct a single-arm, single-center, prospective clinical study enrolling patients diagnoses with pMMR / MSS type middle and low locally advanced rectal cancer who had not received systemic anti-tumor therapy to explore the efficacy and safety of short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody as neoadjuvant therapy.

Conditions

• Rectal Cancer

Interventions

Type	Name	Description
DRUG	Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody	neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.

Timeline

• Start date: 2023-09-01
• Primary completion: 2028-12-31
• Completion: 2029-12-31
• First posted: 2023-08-28
• Last updated: 2023-08-31